ストックスクリーナーアプリを入手
16.73
2.14%
0.35
前日終値:
$16.38
開ける：
$16.43
24時間の取引高:
852.46K
Relative Volume:
0.76
時価総額：
$1.22B
収益：
-
当期純損益:
$-230.32M
株価収益率:
-4.7449
EPS:
-3.5259
ネットキャッシュフロー:
$-196.04M
1週間 パフォーマンス:
-2.62%
1か月 パフォーマンス:
+1.27%
6か月 パフォーマンス:
+65.64%
1年 パフォーマンス:
-59.63%
1日の値動き範囲:
$16.06
$16.85
1週間の範囲:
$16.01
$17.63
52週間の値動き範囲:
$5.95
$62.75
Moonlake Immunotherapeutics Stock (MLTX) Company Profile
Compare MLTX vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MLTX
Moonlake Immunotherapeutics
|
16.73 | 1.22B | 0 | -230.32M | -196.04M | -3.5259 |
VRTX
Vertex Pharmaceuticals Inc
|
423.92 | 107.83B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
701.42 | 73.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
783.50 | 48.72B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.11 | 39.51B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
293.86 | 32.66B | 5.36B | 287.73M | 924.18M | 2.5229 |
Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-23 | アップグレード | Wolfe Research | Underperform → Outperform |
| 2026-03-19 | アップグレード | Rothschild & Co Redburn | Neutral → Buy |
| 2026-01-15 | ダウングレード | Goldman | Neutral → Sell |
| 2026-01-09 | アップグレード | BTIG Research | Neutral → Buy |
| 2025-11-03 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2025-10-02 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2025-10-01 | ダウングレード | Goldman | Buy → Neutral |
| 2025-09-30 | ダウングレード | Citigroup | Buy → Neutral |
| 2025-09-30 | ダウングレード | Wolfe Research | Outperform → Underperform |
| 2025-09-29 | ダウングレード | BTIG Research | Buy → Neutral |
| 2025-09-29 | ダウングレード | Jefferies | Buy → Hold |
| 2025-09-29 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-09-29 | ダウングレード | Stifel | Buy → Hold |
| 2025-07-28 | 開始されました | Rothschild & Co Redburn | Neutral |
| 2025-05-19 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2025-03-18 | 開始されました | RBC Capital Mkts | Outperform |
| 2025-01-17 | アップグレード | Goldman | Neutral → Buy |
| 2024-11-05 | 再開されました | Wedbush | Outperform |
| 2024-08-26 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | 開始されました | Oppenheimer | Outperform |
| 2024-04-02 | 開始されました | Goldman | Neutral |
| 2024-02-15 | 開始されました | Wolfe Research | Outperform |
| 2023-12-08 | 開始されました | Citigroup | Buy |
| 2023-11-02 | 開始されました | Stifel | Buy |
| 2023-09-14 | ダウングレード | Bryan Garnier | Buy → Neutral |
| 2023-08-31 | 開始されました | Needham | Buy |
| 2023-06-15 | 開始されました | Barclays | Equal Weight |
| 2023-05-01 | 開始されました | Guggenheim | Buy |
| 2023-03-22 | 開始されました | Wedbush | Outperform |
| 2023-03-09 | 開始されました | BTIG Research | Buy |
| 2023-02-14 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-02-02 | 開始されました | Bryan Garnier | Buy |
| 2022-11-11 | 開始されました | Jefferies | Buy |
| 2022-08-25 | 開始されました | SVB Leerink | Outperform |
| 2022-07-21 | 開始されました | H.C. Wainwright | Buy |
| 2022-07-07 | 開始されました | Cowen | Outperform |
すべてを表示
Moonlake Immunotherapeutics (MLTX) 最新ニュース
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Short Interest in MoonLake Immunotherapeutics (NASDAQ:MLTX) Decreases By 14.2% - MarketBeat
MLTX Price Today: MoonLake Immunotherapeutics Stock Price, Quote & Chart | MEXC - MEXC Exchange
MoonLake plunges after mixed results from skin disease trial - MSN
MoonLake Immunotherapeutics (MLTX) Proxy Filing Summary - Quartr
MoonLake’s lead asset shows durability in late-stage HS studies - MSN
MLTX stock garners retail attention on buyout speculation, positive skin condition trial data - MSN
MLTX Stock Chart | MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ:MLTX) - ChartMill
Moonlake surges as no additional studies are required for lead drug - MSN
MoonLake Immunotherapeutics (MLTX) price target increased by 11.25% to 22.30 - MSN
Merck made $3B+ offer for MoonLake earlier this yearreport - MSN
Why Is MoonLake Immunotherapeutics Stock Crashing Premarket? - MSN
Understanding the Setup: (MLTX) and Scalable Risk - Stock Traders Daily
MoonLake Immunotherapeutics (NASDAQ: MLTX) puts 6.2% equity plan dilution to shareholder vote - Stock Titan
MoonLake Immunotherapeutics (MLTX) Proxy filing Summary - Quartr
The CEO of MoonLake Immunotherapeutics Dumped Shares Worth $2.8 Million. Should Investors Avoid the Stock? - AOL.com
The CEO of MoonLake Immunotherapeutics Dumped Shares Worth $2.8 Million. Should Investors Avoid the Stock? - The Motley Fool
Have Insiders Sold MoonLake Immunotherapeutics Shares Recently? - Sahm
Insider Sell: Matthias Bodenstedt Sells Shares of MoonLake Immun - GuruFocus
Biotech Fund BVF Trims MoonLake Stake, Sells $63M in Shares - AOL.com
MoonLake (MLTX) CFO sells 2,426 shares under Rule 10b5-1 plan - Stock Titan
H.C. Wainwright reiterates Moonlake stock rating on HS potential By Investing.com - Investing.com Australia
H.C. Wainwright Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $40 - Moomoo
H.C. Wainwright reiterates Moonlake stock rating on HS potential - Investing.com
Major Insider Move at MoonLake Immunotherapeutics Stirs Investor Attention - TipRanks
Insider Sell: CEO Santos da Silva Jorge Sells 150,000 Shares of MoonLake Immunotherapeutics (MLTX) - GuruFocus
MoonLake Immunotherapeutics (NASDAQ:MLTX) CEO Da Silva Jorge Santos Sells 51,873 Shares - MarketBeat
MoonLake Immunotherapeutics (NASDAQ:MLTX) CEO Da Silva Jorge Santos Sells 98,127 Shares - MarketBeat
MoonLake Immunotherapeutics Chief Executive Officer Sold Shares Worth Over $2.7M - TradingView — Track All Markets
MoonLake Immunotherapeutics (NASDAQ: MLTX) CEO sells 150,000 company shares - Stock Titan
Needham Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Positive Risk-Reward and Strategic Momentum Underpin Buy Rating on MoonLake Immunotherapeutics - TipRanks
MoonLake ImmunotherapeuticsClass A Ordinary Shares (NQ: MLTX - The Chronicle-Journal
The Technical Signals Behind (MLTX) That Institutions Follow - Stock Traders Daily
Pre-planned MoonLake (NASDAQ: MLTX) CFO share sale totals 87,795 - Stock Titan
MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Down 6%Here's Why - MarketBeat
Moonlake Immunotherapeutics (MLTX) 財務データ
収益
当期純利益
現金流量
EPS
Moonlake Immunotherapeutics (MLTX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Santos da Silva Jorge | Chief Executive Officer |
Apr 10 '26 |
Sale |
18.41 |
98,127 |
1,806,518 |
2,976,766 |
| Santos da Silva Jorge | Chief Executive Officer |
Apr 13 '26 |
Sale |
18.23 |
51,873 |
945,645 |
2,924,893 |
| Bodenstedt Matthias | Chief Financial Officer |
Apr 09 '26 |
Sale |
18.94 |
85,870 |
1,626,378 |
1,190,435 |
| Bodenstedt Matthias | Chief Financial Officer |
Apr 10 '26 |
Sale |
19.51 |
1,925 |
37,557 |
1,188,510 |
2.45%
大文字化:
|
ボリューム (24 時間):